- Home
- People
- People
Dr Pilar Bilbao discusses possible solutions for stroke patients
Ischaemic strokes cause irreversible damage. They begin suddenly and the damage escalates if the stroke is not treated quickly.Finance & investingInsider Insights III: Willem Blijdorp, Challenges & the Future
In the third and final part of this Insider Insights series, CLINUVEL’s Chair Willem Blijdorp and Professor Kitty Koelemeijer discuss navigating contemporary challenges within a public company...Finance & investingInsider Insights II: Willem Blijdorp, CLINUVEL’s Products, People & Social Purpose
In this second of three Insider Insights, CLINUVEL’s Chair Willem Blijdorp and Professor Kitty Koelemeijer explore the products, people and social purpose of the ASX-listed Group (CUV).Finance & investingInsider Insights: Willem Blijdorp, Chair in a public company
CLINUVEL’s Chair Willem Blijdorp shares his insights on the foundations of the Company and his role as Chair. In this first of three Insider Insights, captured in a discussion between Mr Blijdorp and Professor Kitty Koelemeijer, the history of the business and its position as a public company (ASX: CUV) are in focus.
- R&D
- People
Dr Pilar Bilbao discusses possible solutions for stroke patients
Ischaemic strokes cause irreversible damage. They begin suddenly and the damage escalates if the stroke is not treated quickly.CLINUVEL newsUnderstanding the effects of stroke
CLINUVEL has today announced that its drug afamelanotide was well tolerated by the first three arterial ischaemic stroke (AIS) patients enrolled in a world first clinical trial (CUV801). Watch our new video explaining the pathology and treatment of stroke.PublicationsHas COVID-19 Had an Effect on Sun Protection Behaviours?
Quarantine fatigue amongst the general public may result in a higher incidence rate of sunburn, according to a recent analysis of...R&DPublication brief: Wood’s Light (Wood’s Lamp)
The Wood’s Lamp – invented in 1903 by Baltimore physicist Robert W Wood - is a source of long wave ultraviolet...
- Publications
- Publications
The Weekend Effect – A Worrying Truth or Myth?
Reduced staff over the weekends is the norm for many retail shops, but what about in healthcare? A number of reviews have...PublicationsIs skin cancer in your job description?
Those of us working from offices, or our own homes, aren’t expecting danger pay. However, what about those who have jobs that heighten the risk of getting skin...PublicationsTomatoes and carrots… photoprotection from within?
Most of us have been spun a myth that eating our crusts will make our hair shiny, and that we should...PublicationsHas COVID-19 Had an Effect on Sun Protection Behaviours?
Quarantine fatigue amongst the general public may result in a higher incidence rate of sunburn, according to a recent analysis of...
- Finance & investing
- Announcements
CLINUVEL Confirms AGM Date
CLINUVEL PHARMACEUTICALS LTD (Company) today announces that in light of the restrictions on public gatherings and on international travel and in line with temporary amendments to the Corporations Act 2001 (Cth) in response to the COVID-19 pandemic, the Company’s 2021 Annual General Meeting (AGM) of shareholders will be held as a virtual (online) meetingCLINUVEL newsCLINUVEL Investor Webinar FY2021 Results
CLINUVEL’s Head of Investor Relations, Mr Malcom Bull, leads a discussion with CFO Mr Darren Keamy and CEO Dr Philippe Wolgen follow the release of the Company’s financial results for the year ended 30 June 2021. Held on 26 August 2021 at 1800 Melbourne time.Finance & investingInsider Insights III: Willem Blijdorp, Challenges & the Future
In the third and final part of this Insider Insights series, CLINUVEL’s Chair Willem Blijdorp and Professor Kitty Koelemeijer discuss navigating contemporary challenges within a public company...Finance & investingInsider Insights II: Willem Blijdorp, CLINUVEL’s Products, People & Social Purpose
In this second of three Insider Insights, CLINUVEL’s Chair Willem Blijdorp and Professor Kitty Koelemeijer explore the products, people and social purpose of the ASX-listed Group (CUV).